Takeda Faces $885 Million Liability in Antitrust Verdict

A U.S. jury has found Takeda Pharmaceutical liable for $885 million in damages for delaying a generic drug version of Amitiza through an anticompetitive scheme. This represents the first such verdict against a pharmaceutical company, setting a precedent for class action litigation over 'pay-for-delay' agreements.

A United States jury has found Takeda Pharmaceutical liable for causing $885 million in damages due to delaying a generic version of the drug Amitiza via an anticompetitive scheme. In a landmark decision, jurors in a Boston federal court sided with plaintiffs including pharmacies and retailers like CVS and Walgreens, who argued the delay forced them into overpayment.

The damages could potentially rise to several billion dollars, as U.S. antitrust law could triple the amount. This lawsuit forms part of a broader wave aiming to counter 'pay-for-delay' deals, where branded pharmaceutical firms pay competitors to postpone market entry of cheaper generic variants, resolving patent disputes in the process.

Lawyers for the plaintiffs hailed the verdict as a critical victory, marking the first jury verdict against a pharmaceutical company concerning these deals. Takeda, while denying wrongdoing, may challenge the outcome moving forward as it continues to assert the legitimacy of its actions within competitive negotiation frameworks.